Struggling to feel the joys of motherhood? You are not alone.
Help us study a potential new treatment option for Postpartum Depression.
See If You Qualify
Reunion Neurosciences is the sponsor of the trial. Reunion is a clinical stage pharmaceutical company focused on developing innovative treatments for mental health conditions.
By participating in the RECONNECT Trial, you could contribute to the development of a potential new treatment for postpartum depression that may benefit thousands of women who are experiencing similar symptoms. All trial-related assessments and medical care will be provided at no cost (no insurance required). Eligible participants will receive compensation for time and travel to attend trial visits.
About Postpartum Depression (PPD)
It is estimated that postpartum depression affects 1 in 7 women. PPD encompasses a range of symptoms including feelings of sadness, anxiety, irritability, and exhaustion and can occur at any time during pregnancy or with the first 4 weeks after childbirth.
While resources to support women experiencing PPD are available, existing treatments are not uniformly effective, especially given that every individual’s healing journey is unique. With the RECONNECT Trial, Reunion is exploring a new therapy that may provide fast relief with a single dose, which would enable mothers to resume daily activities with minimal interruptions.
Postpartum depression can have a severe impact on a mother and her family. Prompt recognition and intervention are vital. If you need immediate help, or you feel you may harm yourself or your baby, please call 911 or your local emergency number. You can also call the National Suicide Prevention Hotline, 988, available 24 hours a day.